Flotation/IPO

Entrada Therapeutics files for Nasdaq Listing
The Duchenne muscular dystrophy drug developer's initial public offering could prove an exit ramp for Roche and Merck & Co.
Aura rises to public markets
The Lundbeck, Chiesi Group and Li-Cor Biosciences-backed eye and bladder cancer therapeutics developer has filed to go public on Nasdaq in an offering with a $100m placeholder target.
AutoStore approaches $1.8bn IPO
SoftBank is set to achieve an exit as the warehousing robotics technology developer prepares to go public in Oslo on October 20.
MicroTech Medical meditates on $254m IPO plans
Eli Lilly, Taikang and Tencent are in line to exit the diabetes equipment maker, which has filed to go public in Hong Kong next week.
Starry shines with reverse merger
Quanta Services is contributing to a PIPE deal for the IAC-backed internet service provider’s reverse takeover valuing the combined business at $1.66bn.
Pyxis progresses to stock market
Bayer, Pfizer and Ipsen-backed cancer therapeutics developer Pyxis Oncology priced its shares at the top of its range.
Sonendo files for IPO in New York
The dental technology developer’s proposed listing on the New York Stock Exchange would mark an exit for Henry Crown and Company.
Theseus Pharmaceuticals prices $160m IPO
The Ariad Pharmaceuticals-backed cancer therapeutics developer floated at the top of its range following $120m in venture funding.

Other News

Rigetti regulates $1.5bn reverse merger
The Bloomberg Beta-backed quantum chipmaker is joining forces with the publicly listed Supernova Partners Acquisition Company II.
Exscientia expands IPO to over $350m
The cancer drug developer has closed an initial public offering which took place alongside a $160m SoftBank-led private placement.
Udemy studies IPO option
The Benesse and Prosus-backed online learning platform operator has filed to list on Nasdaq, about a year after closing a series F round at a $3.25bn valuation.
Safie seals public listing
Canon, Kansai Electric Power, Mitsui Fudosan, NEC, NTT Docomo, So-net and T-Gaia were among the investors that scored exits as the CCTV system provider went public.
Xilio Therapeutics targets Nasdaq listing
The immuno-oncology drug developer’s prospective initial public offering would mark exits for Takeda, Merck Group, Ipsen and Merck & Co.
Rent the Runway reveals IPO filing
The fashion rental service has officially filed to go public having raised over $500m from investors including Advance Publications and American Express.

Editor's Picks

Rivian reveals IPO filing
Amazon, Ford, Cox Enterprises and Abdul Latif Jameel each own stakes in the electric vehicle maker sized at 5% or higher, as it targets a reported $80bn valuation in the offering.
Toast tops off $1bn initial public offering
The GV-backed restaurant organisation platform developer has issued $130m in additional shares to close its IPO and has a market capitalisation above $28bn.
Remitly rakes in $523m in IPO
Prosus, Visa, and Prudential Financial scored exits as Remitly went public, with Prudential divesting $32.5m of shares through the offering.
Freshworks' IPO tops $1bn
Alphabet-backed CRM software provider Freshworks floated above its range and now boasts a market cap of $13.5bn.
test reg

Login

Not yet subscribed?

See your subscription offers here